XenoPort, Inc. Data Presented at Digestive Disease Week Meeting Demonstrates Arbaclofen Placarbil Monotherapy Reduces Heartburn and Regurgitation in GERD Patients Previously Treated with PPIs

SANTA CLARA, Calif.--(BUSINESS WIRE)--XenoPort, Inc. (Nasdaq: XNPT) announced today that additional data from a Phase 2 clinical trial demonstrated that arbaclofen placarbil (AP), also known as XP19986, significantly reduced symptoms in gastroesophageal reflux disease (GERD) patients who previously experienced at least a partial response to proton pump inhibitor (PPI) therapy. The data were presented today by Nimish B. Vakil, M.D., FACG, of the University of Wisconsin Medical School at the Digestive Disease Week 2009 annual meeting in Chicago, IL.